Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Vyndamax
| Field | Information |
|---|---|
| Medication Name | Vyndamax |
| Generic Name | Tafamidis |
| Purpose | Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. |
| Mechanism of Action | Stabilizes transthyretin (TTR) tetramers, preventing dissociation into monomers that misfold and aggregate, which leads to amyloid fibril formation and ATTR-CM. |
| Dosage Forms | Oral capsules |
| Available Strengths | 61 mg |
| Dosage Frequency | One capsule daily |
| Common Side Effects | Urinary tract infection, diarrhea, abdominal pain, vaginal infection. |
| Serious Side Effects | None frequently reported, but monitor for signs of allergic reaction or other unusual symptoms. |
| Drug Interactions | Potential interactions with drugs that are substrates of transporters such as BCRP, OAT1, OAT3, OATP1B1, OATP1B3, OAT2B1, OCT1, OCT2, MATE1, and MATE2-K. Consult with your healthcare provider. |
| Important Notes | Vyndamax does not stop the production of amyloid, but stabilizes TTR and slows progression of the disease. Pregnancy status should be discussed with your doctor. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C). Protect from moisture. |
| Missed Dose | Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not double the dose. |
| Alternatives | Vyndaqel (tafamidis meglumine), Onpattro (patisiran), Tegsedi (inotersen). |
Vyndamax Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Vyndaqel (tafamidis meglumine) | TTR stabilizer | An older formulation of tafamidis, taken in a different dosage. |
| Onpattro (patisiran) | RNA interference (RNAi) therapeutic | Targets and reduces the production of TTR protein in the liver, indicated for hereditary ATTR amyloidosis with polyneuropathy. |
| Tegsedi (inotersen) | Antisense oligonucleotide | Also targets and reduces TTR protein production in the liver, indicated for hereditary ATTR amyloidosis with polyneuropathy. |
Vyndamax Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Urinary tract infection | Severe allergic reactions (rash, itching, swelling, difficulty breathing) |
| Diarrhea | Unexplained muscle pain or weakness |
| Abdominal pain | Changes in vision |
| Vaginal infection | Shortness of breath or swelling of ankles/feet |
Vyndamax Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | 61 mg | 61 mg once daily | Swallow the capsule whole; can be taken with or without food. |
Vyndamax Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $500 – $3000 |
| Without Insurance (U.S.) | $22000 |
| From Canada | $14000 |
